Bris­tol My­ers fronts new Schrödinger al­liance with $55M up­front, ex­pand­ing pre­ci­sion on­col­o­gy pro­file

Bris­tol My­ers Squibb has a new R&D part­ner, one to which they’re pay­ing a pret­ty pen­ny to use their dis­cov­ery plat­form.

The phar­ma com­pa­ny is dol­ing out $55 mil­lion up­front to Schrödinger $SD­GR to work on up to five small mol­e­cules, with the po­ten­tial for $2.7 bil­lion in mile­stone pay­ments. Schrödinger’s ini­tial tar­gets in­clude HIF-2 al­pha and SOS1/KRAS for a type of kid­ney can­cer and KRAS-dri­ven can­cers, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER